Peter S.  Garcia net worth and biography

Peter Garcia Biography and Net Worth

CFO of ALX Oncology
Mr. García has served as our Chief Financial Officer since January 2020. Prior to joining us, he served as Vice President and Chief Financial Officer from May 2013 until August 2019 and as Acting Chief Accounting Officer from May 2013 until July 2013 at PDL BioPharma, Inc., an acquirer of royalties and pharmaceutical assets. From October 2011 to May 2013, Mr. García served as Chief Financial Officer at BioTime, Inc., a clinical-stage biotechnology company now known as Lineage Cell Therapeutics. He previously served as Chief Financial Officer of six biotechnology and high technology companies, including Marina Biotech, Nanosys, Nuvelo, Novacept, IntraBiotics Pharmaceuticals and Dendreon. Mr. García holds a B.A. in Economics and Sociology from Stanford University and an M.B.A. from the University of California, Los Angeles.

What is Peter S. Garcia's net worth?

The estimated net worth of Peter S. Garcia is at least $624,560.58 as of June 30th, 2023. Mr. Garcia owns 54,738 shares of ALX Oncology stock worth more than $624,561 as of March 27th. This net worth estimate does not reflect any other investments that Mr. Garcia may own. Additionally, Mr. Garcia receives a salary of $631,110.00 as CFO at ALX Oncology. Learn More about Peter S. Garcia's net worth.

How old is Peter S. Garcia?

Mr. Garcia is currently 62 years old. There are 5 older executives and no younger executives at ALX Oncology. The oldest executive at ALX Oncology is Dr. Corey S. Goodman Ph.D., Executive Chairman, who is 72 years old. Learn More on Peter S. Garcia's age.

What is Peter S. Garcia's salary?

As the CFO of ALX Oncology Holdings Inc., Mr. Garcia earns $631,110.00 per year. There are 2 executives that earn more than Mr. Garcia. The highest earning executive at ALX Oncology is Dr. Jaume Pons Ph.D., Founder, President, Director & Chief Scientific Officer, who commands a salary of $856,290.00 per year. Learn More on Peter S. Garcia's salary.

How do I contact Peter S. Garcia?

The corporate mailing address for Mr. Garcia and other ALX Oncology executives is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. ALX Oncology can also be reached via phone at 650-466-7125 and via email at [email protected]. Learn More on Peter S. Garcia's contact information.

Has Peter S. Garcia been buying or selling shares of ALX Oncology?

Peter S. Garcia has not been actively trading shares of ALX Oncology over the course of the past ninety days. Most recently, Peter S. Garcia sold 887 shares of the business's stock in a transaction on Friday, June 30th. The shares were sold at an average price of $7.34, for a transaction totalling $6,510.58. Following the completion of the sale, the chief financial officer now directly owns 54,738 shares of the company's stock, valued at $401,776.92. Learn More on Peter S. Garcia's trading history.

Who are ALX Oncology's active insiders?

ALX Oncology's insider roster includes Peter Garcia (CFO), Jason Lettmann (Director), Jaume Pons (CEO), and Sophia Randolph (Insider). Learn More on ALX Oncology's active insiders.

Are insiders buying or selling shares of ALX Oncology?

In the last twelve months, ALX Oncology insiders bought shares 1 times. They purchased a total of 4,400 shares worth more than $49,764.00. In the last twelve months, insiders at the sold shares 6 times. They sold a total of 16,228 shares worth more than $130,099.04. The most recent insider tranaction occured on March, 14th when CEO Jason Lettmann bought 4,400 shares worth more than $49,764.00. Insiders at ALX Oncology own 50.3% of the company. Learn More about insider trades at ALX Oncology.

Information on this page was last updated on 3/14/2024.

Peter S. Garcia Insider Trading History at ALX Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2023Sell887$7.34$6,510.5854,738View SEC Filing Icon  
10/18/2021Sell7,229$55.44$400,775.76View SEC Filing Icon  
9/16/2021Sell1,426$80.43$114,693.1810,757View SEC Filing Icon  
8/23/2021Sell60,000$74.15$4,449,000.00View SEC Filing Icon  
8/17/2021Sell10,000$66.23$662,300.00View SEC Filing Icon  
See Full Table

Peter S. Garcia Buying and Selling Activity at ALX Oncology

This chart shows Peter S Garcia's buying and selling at ALX Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ALX Oncology Company Overview

ALX Oncology logo
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $11.31
Low: $11.26
High: $11.45

50 Day Range

MA: $14.15
Low: $10.95
High: $16.79

2 Week Range

Now: $11.31
Low: $3.94
High: $17.42

Volume

6,082 shs

Average Volume

355,182 shs

Market Capitalization

$567.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63